Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tandutinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2013-04-22

Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.

Zhao XQ, Dai CL, Ohnuma S, Liang YJ, Deng W, Chen JJ, Zeng MS, Ambudkar SV, Chen ZS, Fu LW.

Eur J Pharm Sci · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ejps.2013.04.015

Bibliografisk träff 2013-03-22

Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10).

Deng W, Dai CL, Chen JJ, Kathawala RJ, Sun YL, Chen HF, Fu LW, Chen ZS.

Oncol Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3892/or.2013.2362

Bibliografisk träff 2013-02-20

Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.

Ponnurangam S, Standing D, Rangarajan P, Subramaniam D.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-12-0907

Bibliografisk träff 2012-03-01

Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

Ohshima-Hosoyama S, Davare MA, Prajapati SI, Abraham J, Lal S, Nelon LD, Kilcoyne A, Giles FJ, Hanes MA, Rubin BP, Keller C.

J Pediatr Hematol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1097/mph.0b013e3182309fe4

Bibliografisk träff 2010-08-14

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.

Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA.

Invest New Drugs · clinical trial, phase ii; journal article · DOI 10.1007/s10637-010-9516-1

Bibliografisk träff 2008-01-01

Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.

Cheng Y, Paz K.

IDrugs · review; journal article

Bibliografisk träff 2006-04-10

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

Knesl P, Röseling D, Jordis U.

Molecules · research-article; journal article · DOI 10.3390/11040286

Bibliografisk träff 2002-06-01

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA.

Cancer Cell · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/s1535-6108(02)00070-3